A phase i study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154

Leukemia

Volumn 24, Issue 11, 2010, Pages 1893-1900

  Wierda, W G ^a   Castro, J E ^b   Aguillon, R ^b   Sampath, D ^c   Jalayer, A ^a   McMannis, J ^c   Prussak, C E ^d   Keating, M ^a   Kipps, T J ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Memgen LLC   (United States)

Author keywords

adenovirus; CD154; CLL; gene therapy

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; DEATH RECEPTOR 5; FAS ANTIGEN; PROTEIN BID; PROTEIN ISF 35; PROTEIN P73; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; CANCER GENE THERAPY; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPNEA; FEMALE; FLU LIKE SYNDROME; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPOTENSION; INNATE IMMUNITY; LEUKEMIA CELL; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT DISEASE; STOMATITIS; VOMITING;

EID: 78149468313     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.191     Document Type: Article

References (19)

1. 0Brien S. Chronic lymphocytic leukemia. In: DeVita VT, Lawrence TS, Rosenberg SA (eds). Cancer: Principles & Practice of Oncology, 8th edn. Lippincott Williams & Wilkins: Philadelphia, PA, 2008, pp 2278-2291.
2. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-4088.
3. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-980.
4. Hallek M, Fingerle-Rowson G, Fink A-M, Busch R, Mayer J, Hensel M et al. Immunochemotherapy with fludarabine (F), cyclophos-phamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008; 112, (abstract no. 325).
5. Hallek M, Fingerle-Rowson G, Fink A-M, Busch R, Mayer J, Hensel M et al. First-line treatment with fludarabine (F), cyclopho-sphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood 2009; 114, (abstract no. 535).
6. Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756-1765.
7. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993; 177: 925-935.
8. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998; 101: 1133-1141.
9. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917-2924.
10. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA 2008; 105: 3047-3052.
11. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
12. Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lympho-cytic leukemia. Proc Natl Acad Sci USA 2002; 99: 3854-3859.
13. Chu P, Wierda WG, Kipps TJ. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood 2000; 95: 3853-3858.
14. Dicker F, Kater AP, Fukuda T, Kipps TJ. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood 2005; 105: 3193-3198.
15. Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G et al. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 2006; 108: 3450-3457.
16. Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci 2005; 96: 729-737.
17. Pluta A, Nyman U, Joseph B, Robak T, Zhivotovsky B, Smolewski P. The role of p73 in hematological malignancies. Leukemia 2006; 20: 757-766.
18. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005; 12: 1564-1577.
19. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E et al. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia 2010; 24: 563-572.